Cases
Endologix, Inc. (NASDAQ : ELGX)
Securities Class Action
Overview
Overview
- Date:
- 1/4/2017
- Company Name:
- Endologiz, Inc.
- Stock Symbol:
- ELGX
- Class Period:
- FROM 8/2/2016 TO 11/16/2016
- Status:
- Closed/Complete
- Court:
- U.S. District Court: Central California
NEW YORK, January 4, 2017 – Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the United States District Court for the California Central District Court on behalf of all persons or entities who acquired Endologix, Inc. (NASDAQ: ELGX) securities between August 2, 2016 to November 16, 2016 (the “Class Period”).
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Endologix did not have the requisite clinical data for FDA premarket approval of its Nellix® EndoVascular Aneurysm Sealing System; and (2) as a result, Endologix’s public statements were materially false and misleading at all relevant times. On November 16, 2016, Endologix announced that the FDA requested two-year follow-up data on patients enrolled in the EVAS-FORWARD-IDE study to assess Nellix. Following this news, Endologix stock dropped $2.02 per share on November 16, 2016.
If you acquired Endologix securities during the Class Period, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters please contact Melissa A. Fortunato, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Endologix did not have the requisite clinical data for FDA premarket approval of its Nellix® EndoVascular Aneurysm Sealing System; and (2) as a result, Endologix’s public statements were materially false and misleading at all relevant times. On November 16, 2016, Endologix announced that the FDA requested two-year follow-up data on patients enrolled in the EVAS-FORWARD-IDE study to assess Nellix. Following this news, Endologix stock dropped $2.02 per share on November 16, 2016.
If you acquired Endologix securities during the Class Period, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters please contact Melissa A. Fortunato, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.